Updated evidence of Dengzhan Shengmai capsule against ischemic stroke: A systematic review and meta-analysis. (30th January 2022)

• Record Type: Journal Article
• Authors: Liu, Xueyan; Li, Yiqi; Bai, Ningning; Yu, Chuanyu; Xiao, Yun; Li, Chi; Liu, Zhiqiang
• Is Part Of: Journal of ethnopharmacology. Volume 283(2021)
• Publication Date: 2022-01-30
• Subjects: DZSM capsule -- Ischemic stroke -- Randomized controlled trials -- Systematic review -- Meta-analysis; Ethnopharmacology -- Periodicals; Pharmacognosy -- Periodicals; Herbs -- Periodicals; Herbs -- Periodicals; Pharmacognosy -- Periodicals; Pharmacognosie -- Périodiques; Herbes -- Périodiques; 615.1
• DOI: 10.1016/j.jep.2021.114675
• Languages: English
• ISSNs: 0378-8741

Abstract

Abstract: Ethnopharmacological relevance: Ischemic stroke is the most common type of stroke, with high mortality, disability and recurrence rate, which brings a heavy burden to individuals, families and the medical system. Therefore, the intervention and treatment of ischemic stroke are of great significance. Chinese herbal medicine is widely used in treating stroke, for example, Dengzhan shengmai (DZSM) capsule. The current systematic review aims to comprehensively evaluate the efficacy and safety of the DZSM capsule in treating ischemic stroke. Materials and methods: Eligible randomized controlled trials (RCTs) were included to evaluate the efficacy and safety of Chinese herbal medicine DZSM capsule in treating ischemic stroke. Eight electronic databases were searched up to January 27, 2021. The risk ratio (RR), standardized mean difference (SMD), or weighted mean difference (WMD) with 95% confidence interval (CI) were used to assess DZSM capsule treatment outcomes. Results: A total of 28 RCTs involving 6683 participants were included in the systematic review and meta-analysis. Compared with conventional therapy group, DZSM capsule plus conventional therapy improved Barthel Index scores (WMD: 8.97, 95%CI: 5.88–12.05) and reduced modified Rankin Scale (WMD: -0.75, 95%CI: -1.02∼ -0.48), reduced neurological functional deficit scores (WMD: -2.81, 95%CI: -4.17∼ -1.44), recurrence rate (RR: 0.57, 95%CI: 0.44–0.73) and mortality (RR: 0.54, 95%CI: 0.31–0.95), improved clinical effect (RR: 1.18, 95%CI: 1.12–1.24) and quality of life (WMD: 21.67, 95%CI: 6.74–36.61), exhibited a beneficial effect on hemorheology such as elevated levels of APTT (SMD: 1.17, 95%CI: 0.87–1.47) and INR (SMD: 1.12, 95%CI: 0.82–1.42), and on lipid metabolism such as levels of TC (SMD: -0.62, 95%CI: -1.04 ∼ -0.20), TG (SMD: -0.72, 95%CI: -1.18∼ -0.26), LDL (SMD: -1.14, 95%CI: -1.57∼ -0.71) and HDL (SMD: 0.93, 95%CI: 0.36–1.50). No trials reported severe adverse events. Conclusion: DZSM capsule appears to be safe and effective in clinical applications for ischemic stroke. Based on conventional therapy, adding the DZSM capsule could reduce the mortality, recurrence rate, and neurological functional deficit scores, improve clinical effect and quality of life. In addition, compared with conventional therapy, the addition of the DZSM capsule played a beneficial role in hemorheology and lipid metabolism, which may attribute to the potential mechanism. Graphical abstract: Fig. 1 . Graphical abstract. Image 1 Highlights: The latest comprehensive meta-analysis of the efficacy and safety of Dengzhan Shengmai Capsule in patients with ischemic stroke. The first meta-analysis of Dengzhan Shengmai Capsule on cognitive impairment in patients with ischemic stroke. The efficacy of Dengzhan Shengmai Capsule on hemorheology in patients with ischemic stroke was analyzed for the first time. The first meta-analysis of the efficacy of Dengzhan Shengmai Capsule on lipid metabolism in patients with ischemic stroke.